US Attorney scrutinizes Copaxone marketing

Share this article:

The US Attorney's Office for the Southern District of New York is looking into how Teva marketed its MS drug Copaxone and Parkinson's medication Azilect since 2006. The Associated Press reports that the drugmaker announced the investigation Monday and is exploring “possible violations of the False Claims Act.” Citi research analyst Liav Abraham told the AP that the FDA has increased its False Claims investigations over the past few years and that they can take several years to wrap.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.

IRS struggles with device tax

A Treasury report says the IRS is having trouble identifying who owes it money.

White House proposes Hobby Lobby alternative

A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.